What alternative antidepressant can be used for a patient who is not responding to bupropion (Wellbutrin) and experiencing emotional blunting, and is currently taking mirtazapine 7.5 mg nightly?

Switch from Bupropion to an SSRI or SNRI

Given that bupropion is ineffective and causing emotional blunting, switch to a selective serotonin reuptake inhibitor (SSRI) such as sertraline, citalopram, or escitalopram, or alternatively to a serotonergic-noradrenergic antidepressant like venlafaxine or duloxetine. The current mirtazapine 7.5 mg can be continued or increased to a therapeutic dose (15-45 mg) to complement the new antidepressant 1, 2.

Why This Switch Makes Sense

The clinical picture here is paradoxical but important: while bupropion is typically associated with lower rates of emotional blunting compared to SSRIs 2, 3, this patient is experiencing emotional blunting on bupropion specifically. This suggests the medication is simply not working for her depression, and the emotional numbing is likely a manifestation of inadequate treatment response rather than a direct drug effect.

Key evidence from patient reports: Analysis of patient-reported experiences shows that bupropion users actually report very few instances of emotional blunting compared to serotonergic agents 3. However, sertraline, paroxetine, and fluoxetine had high reports of emotional blunting in the same analysis. This creates a clinical dilemma, but the priority is treating the underlying depression effectively.

The Switching Strategy

According to American College of Physicians guidelines, when a patient fails to respond adequately after 6-8 weeks, treatment modification is mandatory 2. The evidence shows that:

• Various pharmacologic switch strategies have similar efficacy for treatment-resistant depression 1
• No single second-generation antidepressant is superior to another based on efficacy alone 2
• Selection should be based on adverse effect profiles, cost, and patient preferences 2

Specific Medication Options:

First-line switch options:

• Duloxetine 60-120 mg daily - Dual serotonin-norepinephrine action; shown effective in SSRI-resistant depression 4
• Venlafaxine 150-225 mg daily - Another SNRI with high patient satisfaction ratings 3
• Sertraline 50-200 mg daily - Well-tolerated SSRI with broad efficacy
• Escitalopram 10-20 mg daily - Clean SSRI with favorable tolerability
• Citalopram 20-40 mg daily - High overall satisfaction in patient reports 3

The Mirtazapine Component

The current mirtazapine dose of 7.5 mg is subtherapeutic and primarily provides sedating/antihistaminic effects. You have two options:

1. Continue at 7.5 mg if sleep is the primary benefit and she tolerates it well
2. Increase to 15-30 mg to achieve antidepressant effects, which could work synergistically with the new SSRI/SNRI 5, 6, 7

The combination of an SSRI/SNRI with mirtazapine is widely used and supported by evidence for treatment-resistant depression 5, 6. Mirtazapine particularly helps with insomnia, decreased appetite, and weight loss 7, making it complementary to most SSRIs/SNRIs.

Critical Monitoring Points

After switching, assess the patient within 1-2 weeks of initiation 2. Monitor specifically for:

• Suicidal ideation (highest risk in first 1-2 months) 2
• Activation symptoms (agitation, irritability, unusual behavior changes) 2
• Blood pressure if using venlafaxine or duloxetine (SNRIs can elevate BP)
• Sexual side effects (common with SSRIs/SNRIs but less so than with paroxetine) 2
• Emotional blunting - ironically, this may worsen initially with SSRIs 3, but should improve as depression lifts

Important Caveats

The emotional blunting paradox: While SSRIs are more commonly associated with emotional blunting than bupropion 3, untreated or undertreated depression itself causes emotional numbing. The goal is to achieve remission, at which point emotional range typically returns. If emotional blunting persists after achieving remission on an SSRI, then consider switching back to bupropion or trying a different mechanism.

Avoid these pitfalls:

• Don't abruptly stop bupropion - taper over 1-2 weeks while starting the new medication
• Don't use subtherapeutic doses - ensure the new antidepressant reaches therapeutic range within 2-4 weeks
• Don't wait too long to reassess - if no improvement by 6-8 weeks at therapeutic dose, modify treatment again 2

Alternative augmentation strategy: If you prefer not to switch entirely, augmenting bupropion with an SSRI/SNRI while continuing both medications is also evidence-based 1, 6, though this increases pill burden and potential drug interactions.